Immuron (IMRN) Liabilities and Shareholders Equity (2015 - 2026)
Immuron (IMRN) posted Liabilities and Shareholders Equity of $13.0 million for Q3 2026, up 28.26% on a QoQ basis from $10.1 million in Q4 2025, and up 12773.76% year-over-year from N/an in Q3 2025.
Powered by 
Analysis
Immuron (IMRN) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends
Immuron has reported Liabilities and Shareholders Equity for 12 years, with the latest figure at $13.0 million in Q3 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 12773.76% year-over-year to $13.0 million in Q3 2026; TTM through Aug 2026 was $29.7 million, a 102.8% increase from a year earlier, with the FY2026 full-year figure at $13.0 million, up 12773.76% from the prior year.
- Liabilities and Shareholders Equity was $13.0 million for Q3 2026 at Immuron, up from $10.1 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $17.8 million in Q2 2022, with the low at $100926.2 in Q3 2025.
- Average Liabilities and Shareholders Equity over 5 years is $7.3 million, with a median of $8.0 million recorded in 2024.
- The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity tumbled 36.69% in 2025, then jumped 12773.76% in 2026.
- Over 5 years, Liabilities and Shareholders Equity stood at $151777.3 in 2022, then slipped by 14.72% to $129434.6 in 2023, then soared by 6048.66% to $8.0 million in 2024, then grew by 27.28% to $10.1 million in 2025, then advanced by 28.26% to $13.0 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $13.0 million (Q3 2026), $10.1 million (Q4 2025), and $100926.2 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.54 Bn | 198.55 Bn | 7.24 Bn | 95.64 Bn |
| 2 | Gilead Sciences | 186.84 Bn | 183.58 Bn | 6.22 Bn | 49.36 Bn |
| 3 | Vertex Pharmaceuticals | 129.39 Bn | 121.54 Bn | 2.84 Bn | 27.42 Bn |
| 4 | Regeneron Pharmaceuticals | 82.05 Bn | 74.06 Bn | 3.93 Bn | 41.73 Bn |
| 5 | Moderna | 69.00 Bn | 63.87 Bn | 52.00 Mn | 10.96 Bn |
| 6 | Argenx Se | 61.15 Bn | 55.97 Bn | 1.37 Bn | 10.03 Bn |
| 7 | Alnylam Pharmaceuticals | 32.67 Bn | 29.37 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Biogen | 32.37 Bn | 31.08 Bn | 1.96 Bn | 32.09 Bn |
| 9 | Roivant Sciences | 28.18 Bn | 28.87 Bn | 1.16 Mn | 5.31 Bn |
| 10 | Immuron | 7.25 Mn | -1.77 Mn | - | 12.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Aug 28, 2026 | 12.99 Mn |
| Dec 31, 2025 | 10.13 Mn |
| Sep 2, 2025 | 100,926.19 |
| Jun 30, 2025 | 6.49 Mn |
| Dec 31, 2024 | 7.96 Mn |
| Sep 9, 2024 | 103,614.89 |
| Jun 30, 2024 | 10.25 Mn |
| Dec 31, 2023 | 129,434.59 |
| Jun 30, 2023 | 14.70 Mn |
| Dec 31, 2022 | 151,777.33 |
| Jun 30, 2022 | 17.80 Mn |
| Dec 31, 2021 | 185,766.29 |
| Jun 30, 2021 | 20.83 Mn |
| Dec 31, 2020 | 6.02 Mn |
| Sep 1, 2020 | 6.02 Mn |
| Jun 30, 2020 | 4.07 Mn |
| Dec 31, 2019 | 62,021.63 |
| Jun 30, 2019 | 6.00 Mn |
| Dec 31, 2018 | 7.70 Mn |
| Jun 30, 2018 | 7.00 Mn |
API Access
Immuron Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=IMRN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "IMRN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=IMRN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();